Patiromer Enables Optimized RAAS Therapy in Heart Failure with CKD
DIAMOND trial confirms potassium binder strategy allows higher doses of spironolactone in patients previously intolerant due to hyperkalemia
Dr. Amara Osei
Cardiorenal Fellow, Cleveland Clinic
◆ CLINICAL BOTTOM LINE
What was studied
Whether patiromer enables initiation or up-titration of spironolactone in HFrEF patients with CKD who had previously discontinued or could not tolerate MRA therapy due to hyperkalemia.
What was found
Patiromer significantly increased the proportion of patients able to receive spironolactone 25–50mg daily (84% vs 43%, p<0.001) with a significant reduction in hyperkalemia events.
What it changes in practice
Potassium binders should be considered a routine enabler of RAAS optimization in CKD patients with HFrEF, not merely a rescue therapy for established hyperkalemia.
The intersection of heart failure and CKD creates one of the most challenging therapeutic dilemmas in internal medicine: the very medications that reduce mortality in heart failure — ACE inhibitors, ARBs, and mineralocorticoid receptor antagonists — are also the primary drivers of hyperkalemia in patients with impaired renal potassium excretion.
The DIAMOND trial addresses this dilemma head-on, asking whether a potassium binder strategy can enable RAAS optimization in patients who have previously been unable to tolerate it.
Study Design
DIAMOND enrolled 878 patients with HFrEF (EF ≤40%) and CKD (eGFR 25–60) who had discontinued or reduced MRA therapy due to hyperkalemia in the prior 12 months. After a run-in phase on patiromer, patients were randomized to continue patiromer or switch to placebo, with spironolactone titration to 25–50mg as tolerated.
Results
The primary endpoint — proportion of patients receiving spironolactone 25–50mg at 27 weeks — was achieved in 84% of patiromer-treated patients versus 43% of placebo-treated patients (p<0.001). Hyperkalemia events (K+ >5.5 mEq/L) occurred in 15% vs 34% respectively.
Clinical Significance
Spironolactone reduces all-cause mortality in HFrEF by approximately 30%. The fact that CKD patients are routinely denied this benefit due to hyperkalemia concerns represents a significant gap in care. DIAMOND provides the strongest evidence yet that this gap can be systematically closed with a potassium binder strategy.
Share this with your patient
Generate a plain-language patient handout based on this article's Clinical Bottom Line. Print it, text it, or paste it into your patient portal — in one tap.
CME Assessment
In DIAMOND, what proportion of patiromer-treated patients were able to receive spironolactone 25–50mg?